• Date: March 08, 2018

The Barcelona company ABAC Therapeutics has closed a Series A financing round worth 16 million euros. Specialised in discovering new antibiotics to combat multidrug-resistant bacteria, ABAC plans to allocate these funds to bring its anti-Acinetobacter baumanii programme to the clinical trial phase.

The aforementioned bacterium is a frequent cause of hospital infections, and it tops the list drawn up by the World Health Organisation of pathogens that urgently require new treatments.

Caixa Capital Risc was one of the participants in this round of financing, together with the Pontifax fund, the Global Health Science Fund, the Debiopharm Innovation Fund and the pharmaceutical company Ferrer.

More news

March 01, 2018

Over a third of the projects selected by Eurostars are related to biotechnology

From the projects that will receive funding in the latest Eurostars call, 36% consist of projects related to innovative products, services or processes in the field of biotechnology.

February 23, 2018

Open call for the CRAASH Barcelona acceleration programme

Launching this month, CRAASH Barcelona is an acceleration programme for innovative projects in the field of medical devices, diagnostics, eHealth and digital health.

February 08, 2018

CaixaImpulse alumnus wins the City of Barcelona Award for Life Sciences

The jury panel decided to award Pere Roca-Cusachs for a paper describing a molecular mechanism that explains how the rigidity of tumour tissues could encourage the survival and spread of cancer cells.